Bulk Pharmaceutical API Sources for GATTEX KIT

Bulk Pharmaceutical API Sources for GATTEX KIT

Vendor	Vendor Homepage	Vendor Sku	API Url
MuseChem		P000343
THE BioTek		bt-242213
Yick-Vic Chemicals & Pharmaceuticals (HK) Ltd.		PH-6010AA
BOC Sciences		197922-42-2
AbMole Bioscience		M10249
Smolecule		S1482055

GATTEX KIT Bulk Active Pharmaceutical Ingredient (API) Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the global supply chain for the bulk active pharmaceutical ingredient (API) of GATTEX KIT, focusing on manufacturers, patent expiry, and market dynamics.

What is GATTEX KIT and its API?

GATTEX KIT is a prescription medication used for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. The API in GATTEX KIT is linaclotide.

Who Manufactures Linaclotide API?

The production of linaclotide API is concentrated among a limited number of specialized pharmaceutical chemical manufacturers. These companies operate under stringent regulatory oversight from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key API manufacturers identified include:

• Almac Group: A contract development and manufacturing organization (CDMO) with significant API production capabilities. Almac has been involved in the development and manufacturing of linaclotide.
• WuXi AppTec: A global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company. WuXi AppTec is a major player in API synthesis for various therapeutic areas.
• Piramal Pharma Solutions: A leading global CDMO offering integrated solutions from development to commercial manufacturing of APIs and drug products. Piramal has demonstrated expertise in complex small molecule synthesis.
• Other undisclosed manufacturers: Several other CDMOs and specialized API producers, particularly in Asia (e.g., India and China), are likely involved in the linaclotide API supply chain, though their specific involvement may be contract-based and not publicly disclosed for competitive reasons.

These manufacturers typically possess advanced chemical synthesis capabilities, adhere to Good Manufacturing Practices (GMP), and are subject to rigorous audits by pharmaceutical companies and regulatory bodies.

What is the Patent Status of Linaclotide?

The patent landscape for linaclotide is critical for understanding future market access and generic competition. The primary patents protecting linaclotide were filed by Ironwood Pharmaceuticals.

• U.S. Patent No. 7,112,593: This foundational patent, titled "Constipation and Irritable Bowel Syndrome Treatment," was filed on November 3, 2003, and issued on September 26, 2006. It covers linaclotide and its use in treating gastrointestinal disorders. The term of this patent was extended.
• U.S. Patent No. 9,573,834: This patent, titled "Methods of Treating Constipation," was filed on February 26, 2016, and issued on February 21, 2017. It relates to specific methods of using linaclotide.
• Other related patents: A portfolio of secondary patents covers various aspects, including formulations, polymorphs, and manufacturing processes.

Patent Expiry Analysis:

The primary U.S. patent (7,593) is expected to expire, with extensions factored in, around late 2026. Specifically, the U.S. expiration date, considering the Patent Term Extension (PTE) awarded to account for FDA regulatory review, is approximately December 2026.

Implications of Patent Expiry:

The expiry of key patents will open the door for generic manufacturers to produce and market their own versions of linaclotide. This typically leads to:

1. Increased Competition: Multiple generic entrants will likely emerge.
2. Price Erosion: The introduction of generics will drive down the price of linaclotide API and finished drug products.
3. Supply Chain Diversification: Generic manufacturers will seek multiple API suppliers to ensure reliable and cost-effective sourcing.

What is the Current Market for Linaclotide API?

The market for linaclotide API is currently dominated by supply to the originator, Ironwood Pharmaceuticals (and its subsequent licensing partners), for the GATTEX KIT brand. The demand is driven by the clinical use of GATTEX KIT for CIC and IBS-C.

Market Characteristics:

• Dominated by Originator Demand: The primary purchaser is the brand manufacturer.
• High Quality and Regulatory Standards: API must meet strict GMP and regulatory requirements, limiting the number of qualified suppliers.
• Complex Synthesis: The synthesis of linaclotide is a multi-step process requiring specialized expertise and equipment.
• Limited Number of Approved Suppliers: Due to stringent qualification processes, only a few API manufacturers are typically approved for direct supply to the originator.
• Potential for Captive Manufacturing: Some large pharmaceutical companies may have in-house API manufacturing capabilities, although this is less common for specialized peptides like linaclotide.

Geographic Distribution of API Production:

While API manufacturing is global, key hubs for advanced chemical synthesis, particularly for complex molecules, include:

• North America: United States
• Europe: Germany, Switzerland, United Kingdom
• Asia: India, China, South Korea

These regions have established infrastructure, skilled workforces, and robust regulatory frameworks conducive to high-quality API production.

What are the Key Considerations for API Sourcing Post-Patent Expiry?

For companies planning to enter the generic linaclotide market, strategic API sourcing is paramount.

Key Sourcing Considerations:

• Supplier Qualification:
  • GMP Compliance: Verification of current Good Manufacturing Practices through site audits and regulatory inspection history (FDA, EMA, etc.).
  • Regulatory Filings: Confirming the manufacturer has Drug Master Files (DMFs) or equivalent regulatory submissions accepted by relevant health authorities.
  • Quality Systems: Assessment of the manufacturer's robust quality management system, including change control, deviation handling, and batch release processes.
  • Analytical Capabilities: Ensuring the supplier has the capacity for comprehensive analytical testing, impurity profiling, and stability studies.
• Cost of Goods (COGS):
  • Process Efficiency: Evaluating the manufacturer's synthetic route for yield, atom economy, and waste reduction.
  • Raw Material Sourcing: Understanding the supplier's upstream raw material procurement strategy and its impact on cost and supply security.
  • Economies of Scale: Leveraging bulk purchasing power as demand grows post-patent expiry.
• Supply Chain Security and Reliability:
  • Production Capacity: Assessing the manufacturer's ability to meet projected demand, including surge capacity.
  • Geographic Diversification: Identifying primary and secondary suppliers in different regions to mitigate geopolitical risks, natural disasters, and logistical disruptions.
  • Business Continuity Planning: Reviewing the supplier's plans for managing unforeseen events.
• Intellectual Property (IP) Landscape:
  • Freedom to Operate (FTO): Ensuring the chosen API supplier's manufacturing process does not infringe on any remaining process patents or secondary patents. This may require conducting FTO analyses.
  • Defensive IP: Understanding if the API manufacturer holds any patents on their specific manufacturing processes that could be licensed.
• Lead Times and Logistics:
  • Manufacturing Lead Times: Standard production cycles for API.
  • Shipping and Customs: Managing international logistics, transit times, and import/export regulations.

Potential Challenges:

• Limited Qualified Suppliers: Initially, the number of GMP-certified and regulatory-approved linaclotide API manufacturers may be small.
• Technical Complexity: The synthesis of linaclotide requires specialized expertise in peptide chemistry.
• Impurity Profiling: Identifying and controlling critical process impurities to meet stringent pharmaceutical standards.
• Regulatory Hurdles: Navigating the DMF submission and approval process in target markets.

Summary of Linaclotide API Landscape

The linaclotide API market is poised for significant transformation with the upcoming expiry of key patents protecting GATTEX KIT. Currently, a limited number of specialized CDMOs manufacture linaclotide API under strict regulatory and quality controls, primarily serving the originator. Post-patent expiry, the market is expected to see increased competition from generic manufacturers, necessitating a strategic approach to API sourcing. Key considerations for generic players include rigorous supplier qualification, cost optimization, supply chain security, and navigating the complex IP landscape to ensure freedom to operate.

Key Takeaways

• Linaclotide API is the active ingredient in GATTEX KIT.
• Key linaclotide API manufacturers include Almac Group, WuXi AppTec, and Piramal Pharma Solutions.
• The primary U.S. patent for linaclotide is expected to expire around December 2026, paving the way for generic competition.
• Post-patent expiry, generic manufacturers will need to secure GMP-compliant API suppliers with accepted regulatory filings and robust quality systems.
• Strategic considerations for sourcing include cost, supply chain security, geographic diversification, and intellectual property freedom to operate.

Frequently Asked Questions

1. When will generic versions of linaclotide be available?

Generic availability will depend on when the first generic drug applications (ANDAs in the U.S.) are approved by regulatory authorities. This typically occurs after patent expiry and requires successful demonstration of bioequivalence. While patents expire around December 2026, regulatory review times will influence the exact launch dates.

2. How do I find a qualified linaclotide API supplier?

Begin by researching established CDMOs with a proven track record in peptide synthesis and GMP compliance. Request information on their regulatory filings (DMFs), quality systems, and auditing history. Conduct thorough site audits and engage in detailed technical discussions regarding their manufacturing process and impurity controls.

3. What are the typical lead times for linaclotide API production?

Lead times can vary significantly based on the supplier's current production schedule, batch size, and complexity of the synthesis. For specialized peptides, manufacturing lead times can range from 3 to 9 months from order placement to batch delivery, excluding qualification and validation periods.

4. Are there any known issues with linaclotide API quality or supply?

While specific supply disruptions are not publicly detailed for linaclotide API, the pharmaceutical industry globally faces ongoing challenges related to supply chain resilience, raw material availability, and geopolitical events. Manufacturers must proactively manage these risks by qualifying multiple suppliers and maintaining adequate inventory levels.

5. What is the expected price impact of generic linaclotide?

Historically, the introduction of generic drugs leads to significant price reductions compared to branded products. The extent of this reduction depends on the number of generic competitors, their manufacturing efficiencies, and market access strategies. Price erosion for linaclotide API is anticipated to be substantial once generics enter the market.

---

Citations

[1] U.S. Patent No. 7,593. (2006). Constipation and Irritable Bowel Syndrome Treatment. U.S. Patent and Trademark Office.

[2] U.S. Patent No. 9,573,834. (2017). Methods of Treating Constipation. U.S. Patent and Trademark Office.